Rifaximin in the treatment of inflammatory bowel disease

Table 1 Rifaximin in inflammatory bowel disease

Ref.	Year	Patient (n)	Study type	Dose (mg)	Duration (wk)	Concomitant medication	Outcome
Crohn’s disease
Shafran et al[22]	2005	29	Open	200 tid	16	Various	Remission up to 59%
Shafran et al[23]	2010	68	Open	200 tid	16	Steroids (46%)	Remission rate up to 65%
Prantera et al[24]	2006	83	Db RCT	800 bid	12	None	Remission rate > placebo
Prantera et al[25]	2010	402	Db RCT	400-1200 bid	12	Various (no steroids)	Remission rate > placebo
Ulcerative colitis (also at 12 wk follow-up)
Guslandi et al[26]	2006	30	Open	400 bid	4	Mesalazine	Remission rate 76%
Gionchetti et al[27]	1999	28	Db	400 bid	10 d	Steroids	Clinical improvement > placebo
Guslandi et al[28]	2010	6	Open, pilot	400 od	12	S.boulardii	Remission maintained in 100%

Db: Double blind; RCT: Randomized controlled trial; >: Significantly higher.